You are here

CF Corrector Ligands Discovered on CF Human Airway Cells

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44DK084658-02A1
Agency Tracking Number: R44DK084658
Amount: $1,379,561.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA10-050
Solicitation Year: 2011
Award Year: 2011
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1500 1ST AVE N, UNIT 37
BIRMINGHAM, AL 35203-1821
United States
DUNS: 807018333
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (205) 934-6234
Business Contact
Phone: (205) 307-6535
Research Institution

DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) achieved Phase 1 SBIR milestones and seeks to continue a mature program that has progressed to the hit-to-lead drug validation, prioritization and progression stage. DBM s major over-archinggoal for this program is to identify novel clinical candidate CFTR Corrector Ligands (CFCLs) for the treatment of CF through the completion of a focused Drug Discovery program and accompanying Critical Progression Path, which utilize disease-relevant humancell systems. These compounds have the potential to be disease-modifying with dramatic effects on disease progression as well as CF patients well-being and quality of life. DBM, academic collaborators, and industry consultants (with gt70 years experiencein Drug Discovery) have refined secondary validation and tertiary prioritization assays and their order in a Critical Path such that the small molecules that are most potent and druggable are systematically identified and progressed forward towards selection of the best compound(s) for progression to Preclinical Development. Phase 2 aims will focus on identifying and progressing the best lead CFCLs from different chemical scaffolds. This CF Drug Discovery program is part of a larger initiative on CF and other chronic respiratory diseases that represent DBM s most mature drug discovery umbrella to date (see Commercialization Plan). For this revised Phase 2 SBIR-driven program application, DBM proposes three key milestones, which follow a Drug Discovery Critical Path of validation, optimization and, ultimately, the selection of inhaled clinical candidate compounds primarily (with an eye on secondary examination of the oral route of administration): Milestone 1 - Hit to Lead Validation, which will profile emerging hit-to-lead CF corrector ligands in comparison to a potent benchmark lead compound identified in Phase 1, DBM 99H7. Milestone 2 - Structure-Activity Relationship (SAR) Development and Lead Optimization, which will profile further and optimize the lead CF corrector compounds. Milestone 3 - Further Profiling of Lead Compounds and Selection of Clinical Candidate(s), which will identify the best compounds for Preclinical Development and Clinical Trials. Specific aims, listed under each key milestone, script key experimental tasks within the Drug Discovery Critical Path; these are defined in more detail elsewhere in Goals and Milestones and Research Strategy sections. They represent key parameters and features of compounds that will assist with the identification of the best CFCLs. Mechanistically, the most desired drug is one that both corrects the folding defect in delF508-CFTR within the endoplasmic reticulum as well as activates or opens the delF508-CFTR Cl- channel in the secretory pathway and atthe apical plasma membrane. Added benefits may include the correction of other dysregulated epithelial cell functions, such as inhibition of hyperactive epithelial sodium channels (the ENaCs) as well as the opening or up- regulation of other Cl- channels that might amplify mutant CFTR function in the apical cell membrane. DBM believes that its benchmark lead CFCL drug, DBM 99H7, is an example of a delF508-CFTR corrector, a delF508- CFTR opener, and an ENaC inhibitor. Through the study of initial lead and lead classes of CFCLs found in this CF human airway cell-driven drug discovery program during Phase1 of the SBIR grant, we have learned much about the features of lead drugs that are most desired and how to best profile and progress them. DBM is confident that this Phase 2 program will yield a primary CFCL clinical candidate as well as back-up lead CFCLs to progress forward into a therapeutic development spinout company and, ultimately, to out-license with a BioPharma. DBM, Inc. PUBLIC HEALTH RELEVANCE: Cystic fibrosis is a progressive and debilitating lung disease that afflicts children and young adults; it causes significant morbidity and premature mortality with an average life-span of 32 years. Loss of salt and fluid secretion together with accelerated salt absorption dehydrates the airways and causes sticky mucus to accumulate. This accumulation eventually obstructs airflow, which leads to pulmonary decline in CF patients, and provides an ideal environment for infectious bacteria to colonize and cause recurrent disease exacerbations. DiscoveryBioMed, Inc., our team of academic partners from two national CF Research Centers, and industry consultant professionals derived from GlaxoSmithKline and AstraZeneca seek to garner continued funding to validate, prioritize and select the best CFTR corrector/opener ligands as new and effective CF drugs. Our program is discovering and 'progressing' compounds in CF human lung cell systems that restore normal function of multiple CF cell dysfunctions to attenuate and, ultimately, prevent the development of CF lung disease by attacking its root causes at the cellular and molecular level of the CF airways epithelium and the airway microenvironment. These compounds have the potential to be disease- modifying with dramatic effects on disease progression as well as CF patients' well-being and quality of life. DBM, Inc.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government